This issue implies a major gap in our ability to reproduce the context and mechanisms regulating TGF‐β signalling levels in human cancers when evaluating the efficacy of TGF‐β signalling inhibitors in pre‐clinical cancer models. Here, TGFB1 is linked to cancer.